Advanced search    

Search: authors:"Nadia Harbeck"

3 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

O'Shaughnessy 8 Robert M. Beck 4 Amy Ko 4 Markus F. Renschler 4 Debora Barton 4 Nadia Harbeck 7 0 Weston Park Hospital, Sheffield Cancer Research Center , Sheffield, England 1 University of Pittsburgh Medical

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

. Nabholtz 3 Joyce O'Shaughnessy 8 Robert M. Beck 4 Amy Ko 4 Markus F. Renschler 4 Debora Barton 4 Nadia Harbeck 7 0 Weston Park Hospital, Sheffield Cancer Research Center , Sheffield, England 1 University of

WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial

Background Adjuvant treatment decision-making based on conventional clinical/pathological and prognostic single molecular markers or genomic signatures is a therapeutic area in which over-/under-treatment are still key clinical problems even though substantial and continuous improvement of outcome has been achieved over the past decades. Response to therapy is currently not...